Neurocrine Biosciences Reports Second Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq end lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Needham Starts NeoVolta (NEOV) at Buy
Neurocrine Biosciences (NBIX) Tops Q2 EPS by 43c, Revenues Beat
July 29, 2019 4:54 PM EDTNeurocrine Biosciences (NASDAQ: NBIX) reported Q2 EPS of $0.54, $0.43 better than the analyst estimate of $0.11. Revenue for the quarter came in at $183.6 million versus the consensus estimate of $163.14 million.
"Over the past two years, our team has done an excellent job building awareness of tardive dyskinesia within the healthcare community and providing patients... More
